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Diabetic nephropathy is a common complication of diabetes mellitus. Transforming
growth factor beta 1 (TGF-b1) is considered to be one of the major cytokines involved in the
regulation of extracellular matrix (ECM) synthesis and degradation. Discrepant results
were reported for urine TGF-b1 in diabetic patients. The aim of the present study is to
investigate urine and serum TGF-b1 in patients with type II diabetes with and without
nephropathy.
The study was performed on 72 patients with type II diabetes (26 macroalbuminuria, 27
microalbuminuria and 19 normoalbuminuria) together with 30 healthy subjects to serve as
controls. Urinary and serum TGF-b1 and urine albumin were investigated by Elisa, plasma
glucose, whole blood glycated hemoglobin, Urinary and serum total protein, creatinine,
were determined by colorimetric methods. Urine and serum TGF-b1 were significantly
increased in all diabetic groups being more pronounced in the macroalbuminuria group
than micro and normoalbuminuria groups. Also urine total protein was increased, being
more pronounced in macroalbuminuria group than other groups. Urinary and serum TGF-
b1 showed high positive correlation with urinary total protein concentration in macro and
microalbuminuria groups r ¼ (0.9, 0.9, 0.8 and 0.89) respectively. The results revealed sig-
nificant increase in Urinary and serum TGF-b1 and their concentrations in urine were
parallel to urine proteins and albumin concentrations; urinary and serum TGF-b1 showed
high positive correlation with urinary total protein, so it could be used as a marker with
total protein and albumin to confirm the diabetic nephropathy in type II diabetic patients.
Copyright 2014, Beni-Suef University. Production and hosting by Elsevier B.V. All rights reserved.(N.S. Hussein).
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Diabetes mellitus is a metabolic disease, which is character-
ized by high glucose levels in blood (hyperglycemia) and urine
(glucosuria). Diabetes affects more than 170 million people
worldwide and the number will rise to 370 million people by
2030. About one third of those affected, will eventually have
progressive deterioration of renal function (Chen et al., 2013).
A long standing diabetic state of diabetesmellitus can result in
several severe chronic complications: cardiovascular compli-
cations, diabetic retinopathy, diabetic neuropathy and dia-
betic nephropathy (Ramezani et al., 2007). Diabetic
nephropathy (DN) is one of the most severe complications of
diabetes mellitus (El Mesallamy et al., 2008). The classical
definition of diabetic nephropathy is a progressive rise in
urine albumin excretion, coupled with increasing blood
pressure, leading to declining glomerular filtration and even-
tually end stage kidney failure (Obineche and Adem, 2005).
Diabetic nephropathy is characterized structurally by renal
hypertrophy and by progressive mesangial deposition of
extracellular matrix (ECM) characterizing glomerulosclerosis,
which is associated with progressive glomerular capillary
occlusion, albuminuria and a progressive fall in glomerular
filtration rate (GFR). Overt diabetic nephropathy is character-
ized by persistent proteinuria (>500 mg/24 h) or macro-
albuminuria (>300 mg/24 h) (Rivarola et al., 1999). In the
natural history of the disease, proteinuria is preceded by
stages of excessive glomerular filtration and of micro-
albuminuria (30e300mg/24 h), which signals an increased risk
of progression to overt nephropathy (Williams, 2005). The
degree of proteinuria correlates with the progression of glo-
merulosclerosis and tubulointerstitial fibrosis (Wolf and
Ziyadeh, 2007).
Transforming growth factor beta (TGF-b1) is a multifunc-
tional cytokine implicated in the pathogenesis of many forms
of progressive renal disease, including diabetic nephropathy
(McKnight et al., 2007). TGF-b1 directly stimulates the tran-
scription of many extracellular matrix genes in renal cells
including mesangial, endothelial and tubular cells. In addi-
tion, it decreases collagenase production and simultaneously
stimulates expression of tissue inhibitors of metal-
loproteinases, resulting in inhibition of extracellular matrix
turnover. Deposition of extracellular matrix components,
including fibronectin and collagen types I, III and IV, is an
important component of the scarring observed during the
progression of glomerulosclerosis and tubulointerstitial
fibrosis. An increase in the synthesis as well as a decrease in
turnover of these proteins is responsible for the net accumu-
lation of extracellular matrix (Fukuda et al., 2009).
A number of molecular mediators and intracellular
signaling pathways that have been identified in diabetic kidney
injury have been found to stimulate the renal TGF-b1 activity as
an intermediary step. These mediators are: high glucose con-
centration, early and advanced products of nonenzymatic gly-
cation of proteins, oxidative stress, glomerular hypertension,
de novo synthesis of diacylglycerol and protein kinase C acti-
vation, glucosamine overproduction, and high levels of vaso-
active substances such as intrarenal angiotensin II, endothelin,
and thromboxane (Ziyadeh, 2004). Several clinical studies haveestablished that TGF-b1 is increased in the kidneys of diabetic
patients (Sharma and McGowan, 2000). Urinary TGF-b1 mea-
surement has been suggested as a marker for diabetic ne-
phropathy in some studies as reported by Sato et al. (1998) who
found higher TGF-b1 excretion in diabetic patients well corre-
lated to the state of nephropathy, other studies have not shown
the association of urinary TGF-b1 with diabetic nephropathy as
reported by Eija et al. (2000) who did not find difference in uri-
nary TGF-b1 excretion between microalbuminuric and nor-
moalbuminuric patients.
The aim of the present work is to study the role of TGF-b1
as biochemical marker in diabetic nephropathy which was
monitored by glycemic status and kidney function measure-
ments and to explore the correlation between serum TGF-b1
and urinary TGF-b1 in diabetic nephropathy although it has
been suggested as a marker for diabetic nephropathy not all
studies had shown the association of urinary TGF-b1 with
nephropathy.2. Patients and methods
2.1. Patients
This study included 102 subjects which classified into 2 main
groups.
Group (I): thirty adult hypertensive healthy volunteers
served as control. They were on antihypertensive therapy
with captopril. The control group was selected as hyperten-
sive healthy subjects since all the diabetic patients in group II
were hypertensive. The systolic and diastolic BP values for all
subjects were shown in Table 1.
Group (II): seventy two previously diagnosed type 2 diabetic
patients from outpatients’ clinic of the National Institute for
Urology and Nephrology, Cairo, Egypt. All type 2 diabetic pa-
tientsmet the criteria of AmericanDiabetes Association (ADA)
for type 2 diabetes. All type 2 diabetic subjects were not
receiving anymedications other than hypoglycemic drugs and
hypotensive drug (Captopril) and were not complaining of any
chronic or acute illness.
This group was subdivided into the following subgroups
according to albumin excretion rate (AER):
 Group IIa nineteen diabetic patients with normoalbumi-
nuria having (AER<30 mg/g creatinine).
 Group IIb Twenty seven diabetic patients with micro-
albuminuria having (AER 30e300 mg/g creatinine).
 Group IIc Twenty six diabetic patients with macro-
albuminuria having (AER > 300 mg/g creatinine).
Full history including age, sex, diabetic duration and treat-
ment were recorded for all subjects. The studied groups were
matched as regards age and sex.Written informed consentwas
obtained from the subjects and this study was approved by the
Ethics Committee of the National Research Center.
2.2. Exclusion criteria
Chronic liver diseases, heart diseases, coronary artery dis-
eases (CAD),malignancy, autoimmune diseases, chronic renal
Table 1eDemographic and bio-clinical characteristics of healthy control subjects (group I) and diabetic patients (groups IIa,
IIb and IIc).
Parameter Group I Group IIa Group IIb Group IIc
Number 30 19 27 26
Age (years) 48.2  8.1 54.3  6.9 55.8  7.9 55.5  4.9
Sex (M/F) 18/12 10/9 18/9 12/14
DM duration (years) e 9.3  6.5 10.4  5.2 13.6  5.7b,c:*
No. of patients receiving Insulin/Oral therapy e 7/12 14/13 17/9
Systolic blood pressure (mm Hg) 132.3  6.2 133.1  8.2 132.5  11.2 132.3  11.7
Diastolic blood pressure (mm Hg) 80.6  6.9 80.5  9.1 79.6  7.5 80.7  10.1
Fasting plasma glucose (mg/dl) 88.7  11.3 177.6  60.3 194.2  52a:*** 198.1  57.8a:***
Glycated hemoglobin (%) 7.2  0.5 9.3  1.4 11.6  2.6a:***,b:* 10.1  1.9a:***,c:*
Data are expressed as mean  SD, a: significant difference from healthy group (group I), b: significant difference from diabetic normoalbu-
minuria (group IIa), c: significant difference from diabetic microalbuminuria (group IIb). *: P < 0.05, **: P < 0.01, ***: P < 0.001.
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chronic inflammatory diseases and patients taking any anti-
inflammatory drugs, nonsteroidal anti-inflammatory drugs
(NSAIDs) or other medications that may affect the kidney.
2.3. Samples collection and biochemical analysis
Blood samples were drawn in the morning after a 12 h fast
(from 8 pm to 8 am); a portion of the blood was collected on
EDTA for the determination of glycated hemoglubin. The
other portion left to clot and serum was separated for the
other determinations. Morning urine samples were collected,
the urine was centrifuged at 1000 rpm, and the supernatant
was used for biochemical analysis.
2.4. Methods
Fasting plasma glucose was determined by enzymatic colori-
metric method performed according to Trinder reaction using
a Kit provided by linear chemicals (Barcelona-Spain). Glycated
hemoglobin was measured in whole blood chromatographi-
cally and colorimetrically using a kit obtained from inter-
medical (Italy). Serum and urine creatinine were measured
calorimetrically by the reaction of creatinine in serumor urine
with picric acid in alkaline condition to form a yellow-orange
color complex (Jaffe reaction), using a kit obtained from Bio-
MED diagnostics (Egypt). Urine total proteins were measured
colorimetrically using a kit obtained from Linear chemicals
(Barcelona-Spain). Albuminuria was determined by ELISA
using a kit provided by DRGDiagnostics (USA) according to the
method of Walker et al. (1992). Urine and serum TGF-b1 was
measured by ELISA using a kit provided by RayBiotech (USA)
according to the method of Kropf et al. (1997).
2.5. Statistical analysis
All statistical analyses were performed using the SPSS version
17. The data were expressed as Mean  standard deviation
(SD). Individual groups were compared using Student T-test
and different groups were compared using analysis of vari-
ance (ANOVA) followed by b Bonferroni post hoc test to
compare individual groups. Moreover, correlations between
different parameters were evaluated by Pearson’s correlation(r), Receiver operator characteristic (ROC)-curve analysis was
used to establish the cut-off values for TGF-b1.3. Results
In diabetic groups, the diabetic patients with macro-
albuminuria showed a significant long duration of diabetes in
comparison with micro-albuminuria and normo-albuminuria
(P < 0.05). Fasting plasma glucose and glycated hemoglobin
were significantly increased in macroalbuminuria and
microalbuminuria in comparison with healthy control group
(P < 0.001). On the other hand, in macroalbuminuria group
there was an elevation in fasting plasma glucose in compari-
son with microalbuminuria and normoalbuminuria
groups (Table 1).
The macroalbuminuria group and the microalbuminuria
group showed highly significant increase in urinary total
protein concentration and urinary albumin concentration in
comparisonwith both normoalbuminuria and healthy control
groups (P < 0.001). As regards urinary creatinine the macro-
albuminuria group showed highly significant decrease in
comparison with the normoalbuminuria group (P < 0.001),
also the microalbuminuria group showed a significant
decrease in comparison with the normoalbuminuria group
(P < 0.01), while there is no statistical significant difference
between the microalbuminuria and the healthy control group
(Table 2). The high concentrations of urinary creatinine were
in the normoalbuminuria and the healthy control groups and
the low concentration were in the macroalbuminuria and
microalbuminuria. Albumin/creatinine ratio and total pro-
tein/creatinine ratio showed significant increase in macro-
albuminuria and microalbuminuria when compared with
normoalbuminuria and healthy control groups (P < 0.001).
Regarding serum total protein, the healthy control and nor-
moalbuminuria groups showed highly significant increase in
comparison with macroalbuminuria group (P < 0.001). Being
the largest concentration of serum total protein was in the
healthy control group followed by the normoalbuminuria
then the microalbuminuria groups, and the least concentra-
tion was in the macroalbuminuria group. Serum creatinine
concentration showed significant increase in macro-
albuminuria in comparison with both microalbuminuria and
Table 3 e Urine and serum TGF-b1 data of healthy control subjects (group I) and diabetic patients (groups IIa, IIb and IIc).
Parameter Gp I Gp IIa Gp IIb Gp IIc
U. TGF-b1 (pg/g creatinine) Mean  SD 8  3.7 13.1  6.6 31.7  18.6a,b;*** 237.8  176.2a,b,c;***
S. TGF-b1 (pg/ml) Mean  SD 16.2  6 23.3  15.9 201  79.1a,b:*** 2212.4  1770a,b,c;***
a: significant difference from healthy group (group I), b: significant difference from diabetic normoalbuminuria (group IIa), c: significant dif-
ference from diabetic microalbuminuria (group IIb). *: P < 0.05, **: P < 0.01, ***: P < 0.001.
Table 2 e Biochemical data of healthy control subjects (group I) and diabetic patients (groups IIa, IIb and IIc).
Parameter Gp I Gp IIa Gp IIb Gp IIc
U. Total protein (mg/l) Mean  SD 63.9  13.6 148.2  52 403.8  158a,b:*** 2770  1614a,b,c:***
U. Creatinine (g/l) Mean  SD 1.2  0.6 1.7  0.6 1  0.7b:** 0.8  0.4a:*,b:***
U. Total protein/Creatinine (mg/g) Mean  SD 63.9  35.5 92.8  27.8 472.4  212a,b:*** 3652.4  2159.3a,b,c:***
U. Albumin (mg/l) Mean  SD 6.6  1.4 35  15.1 126.3  45.3a,b:*** 744.3  245.3a,b,c:***
U. Albumin/Creatinine (mg/g) Mean  SD 7  4.5 21  6 151.2  74.4a,b:*** 1028.4  423.8a,b,c:***
S. Total protein (g/l) Mean  SD 71.2  7.6 71  6.8 67.7  5.5 63.1  10.5a,b:**
S. Creatinine (mg/dl) Mean  SD 0.9  0.2 1.02  0.1 0.9  0.2b:* 1.1  0.4a,c:*
Data are expressed as mean  SD, a: significant difference from healthy group (group I), b: significant difference from diabetic normoalbu-
minuria (group IIa), c: significant difference from diabetic microalbuminuria (group IIb). *: P < 0.05, **: P < 0.01, ***: P < 0.001.
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ence in mean concentrations of microalbuminuria and
healthy control groups (Table 2).
Urinary and Serum TGF-b1 showed statistical significant
difference inmacroalbuminuria group in comparisonwith the
microalbuminuria, normoalbuminuria and healthy control
groups (P < 0.001). Also the microalbuminuria group showed
statistical significant increase in comparison with both
normoalbuminuria and healthy control groups (P < 0.001)
(Table 3).
The results revealed that urinary and serum TGF-b1 were
positively correlated with glucose concentration inmacro and
microalbuminuria groups r ¼ (0.9, 0.76, 0.77 and 0.73) respec-
tively, Figs. 1 and 2. Also correlated with glycated hemoglobin
concentration in macro and microalbuminuria groups
r ¼ (0.93, 0.56, 0.82 and 0.67) respectively. While in normoal-
buminuria and healthy groups there were no correlations
(Figs. 3 and 4).
Urinary and serum TGF-b1 showed weak correlation with
duration of diabetes mellitus in macro, micro and normoal-
buminuria groups r¼ (0.2, 0.3, 0.3, 0.2, 0.2 and 0.4) respectively.Fig. 1 e Correlation between urinary TGF-b1 and Plasma glucos
microalbuminuria (b).Urinary and serum TGF-b1 denoting high positive correla-
tion with urinary total protein concentration in macro, micro
and normoalbuminuria groups r ¼ (0.9, 0.9, 0.7, 0.8, 0.89 and
0.73) respectively, also high positive correlation with urinary
albumin concentration in macro, micro and normoalbumi-
nuria groups r ¼ (0.87, 0.78, 0.81, 0.8, 0.84 and 0.79) respec-
tively, while no and weak correlation with healthy control
group.
Significant positive correlations were observed between
both urinary and serum TGF-b1 and proteinuria/creatinine
ratio in diabetic nephropathy patients r ¼ (0.76 and 0.77)
respectively (Fig. 5). Also, significant positive correlations
were detected between both urinary and serum TGF-b1 and
albuminuria/creatinine ratio in diabetic nephropathy patients
r ¼ (0.62 and 0.64) respectively (Fig. 6). While there were no
correlations in diabetic nonnephropathy patients and healthy
control subjects.
Urinary and serum TGF-b1 showed a positive correlation
with urinary creatinine in macro, micro and normoalbumi-
nuria groups (r ¼ 0.49, 0.49, 0.6, 0.37, 0.47 and 0.5) respectively,
but with a negative correlation in healthy control group.e in diabetic patients with macroalbuminuria (a) and
Fig. 2 e Correlation between serum TGF-b1 and Plasma glucose in diabetic patients with macroalbuminuria (a) and
microalbuminuria (b).
Fig. 3 e Correlation between urinary TGF-b1 and glycated hemoglobin in diabetic patients with macroalbuminuria (a) and
microalbuminuria (b).
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correlation with serum creatinine (r ¼ 0.002e0.224) in macro,
micro and normoalbuminuria groups and with no correlation
with the healthy control group.Fig. 4 e Correlation between serum TGF-b1 and glycated hemo
microalbuminuria (b).Urinary TGF-b1 showed high positive correlation with
serum TGF-b1 (r ¼ 0.86, 0.93 and 0.89) in macro, micro and
normoalbuminuria groups respectively but with weak corre-
lation in healthy control group (r ¼ 0.269).globin in diabetic patients with macroalbuminuria (a) and
Fig. 5 e Correlation between both urinary (a) and serum (b) TGF-b1 and total protein/creatinine ratio in type II diabetic
nephropathy patients.
Fig. 6 e Correlation between both urinary (a) and serum (b) TGF-b1 and albumin/creatinine ratio in type II diabetic
nephropathy patients.
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and 0.931 respectively as regards urinary TGF-b1 -(cutoff point
was 20.9). While the sensitivity, specificity and accuracy were
100%, 73.5 and 0.872 respectively as regards serum TGF-b1
(cutoff point was 25.15) (Fig. 7).4. Discussion
The present study was designed to evaluate the value of TGF-
b1 as a biochemical marker for diabetic nephropathy in type II
diabetic patients. The present work showed that urinary and
serum TGF-b1 levels were significantly increased in diabetic
macro and microalbuminuria groups when compared with
healthy control subjects and that was confirmed by the posi-
tive significant correlations between both glucose concentra-
tion and glycated hemoglobin and both urinary and serum
TGF-b1, and these results agreed with Hellmich et al. (2000),
Hefini et al. (2007) and El Mesallamy et al. (2012). TGF-b1
concentration increased in diabetic patients with albuminuria
whether macro or microalbuminuria (diabetic patients with
nephropathy) not with diabetic normoalbuminuria (diabetic
patients without nephropathy) or control subject who were
hypertensive, these results were supported by Yaqiu et al.(2001) who concluded that the serum concentration of TGF-
b1 has started to increase in the early stages of diabetic ne-
phropathy andwith the development of diabetic nephropathy
the serum level of TGF-b1 significantly increased.
Urinary and serum TGF-b1 showed correlation with dura-
tion of diabetes. The mean duration of diabetes is greater in
macroalbuminuria when compared with both normoalbumi-
nuria and microalbuminuria groups. These results are in
agreement with El Mesallamy et al. (2012) who found that
diabetic patient with microalbuminuria and macro-
albuminuria showed a significant long duration of diabetes in
comparison with normoalbuminuria.
Significant positive correlations were found between the
concentration of TGF-b1 in urine and both proteinuria and
albuminuria in patients with type II diabetes, these results
agreed with Rivarola et al. (1999) and Hefini et al. (2007),
however there were wide variations in the rate of urinary and
serum TGF-b1 concentrations in these patients which may be
due to that the patients were presented with different stages
of nephropathy. Several studies have shown that TGF-b1 may
play a major role in glomerular disease mediating the in-
flammatory response through glomerulosclerosis (Coimbra
et al., 1991; Border et al., 1992, Yamamoto et al., 1993;
Bertoluci et al., 1996), but there are some observations
U.TGF-β1 (Gp I+Gp IIa)/Gp II b+c) 
a
S.TGF-β1 (Gp I+Gp IIa)/Gp II b+c) 
b
Fig. 7 e ROC curve of urinary (a) and serum (b) TGF-b1.
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thesis and not from ultrafiltration or secretions (Noh et al.,
1993; Dominguez et al., 1998; Grainger et al., 1995). Also
these results may coincide with the result that urinary and
serum TGF-b1 were negatively correlated with the serum total
protein in macro, micro and normoalbuminuria groups with
no significant correlationwith the health control subjects, and
this may denote loss of big amount of protein in urine hence
its scanty in serum of diabetic patients.
The present study showed low mean concentration of
urinary creatinine in themacro andmicroalbuminuria groups
and relatively high mean concentration of urinary creatinine
in the normoalbuminuria and healthy control groups. In the
present study high levels of serum creatinine were detected in
the macroalbuminuria group, while lower levels were detec-
ted in the healthy and microalbuminuria groups. These vari-
ability in the results of urinary and serum creatinine may be
attributed to the occurrence of low glomerular filtration rate,
which result from renal hypertrophy, progressive mesangial
deposition of extracellular matrix (ECM) and progressive
glomerular capillary occlusion. The factors responsible for the
deposition and accumulation of extracellular matrix material
within the kidney are hyperglycemia, glycated proteins,
vasoactive hormones, systemic and glomerular hypertension,
proteinuria, growth factors, and cytokines which have been
implicated in the pathogenesis of diabetic nephropathy
(Reeves and Andreoli, 2000).5. Conclusion
It is well known fact that the onset of type II diabetes is
insidious, and by time of diagnosis many patients may
develop overt nephropathy, hence the present study recom-
mends screening for urinary and/or serum TGF-b1 concen-
tration as soon as diabetes is firstly diagnosed with regular
follow up screening for TGF-b1 afterwards. Thus, this may be
considered as biochemical marker that can be used to esti-
mate the progression of diabetes to diabetic nephropathy.Acknowledgments
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